Lorigerlimab - MacroGenics
Alternative Names: AEX1344; EXPASY; MGD-019; PD-1 x CTLA-4 bispecific DART moleculeLatest Information Update: 28 May 2025
At a glance
- Originator MacroGenics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer; Solid tumours
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral)
- 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Bulgaria (Parenteral)
- 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Poland (Parenteral)